News

Nancy Lurker, spoke with our team about the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 at the 2023 ASRS annual meeting.

Paul Hahn, MD, PhD, spoke with our team about comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy at the 2023 ASRS annual meeting.

The trial is a prospective, multi-center, open label, single-armed trial which plans on enrolling 24 eligible subjects with cystoid macular edema.

Even when wearing their glasses or contact lenses, individuals who scored worse on vision tests were also more likely to have concerning scores on cognitive tests.

Russ Trenary, President and CEO at Outlook Therapeutics spoke with our team to share information on the company's work toward FDA approval for Bevacizumab at the 2023 ASRS annual meeting.

The latest TikTok trend of microwaving hard-boiled eggs and slicing them, causing it to explode, could have ophthalmologists see an influx of injured patients.

The scholarships will be worth $1000 each and “aim to recognize innovation in myopia management and specialty contact lenses.”

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle for the treatment of geographic atrophy at the 2023 ASRS annual meeting.

The companies are partnering to advance a novel therapy with the goal of preserving sight for people living with blinding retinal disease.

The Vanderbilt University Medical Center study contradicts earlier studies from East Asia that showed the small dose of atropine is effective in slowing progression of myopia.

Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team to share information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases at the 2023 ASRS annual meeting.

This marks the 22nd time, and the 20th consecutive year, Bascom Palmer has received the No. 1 ranking by US News & World Report since the publication began surveying US physicians for its annual "Best Hospitals" rankings 34 years ago.

The trial will be an open-label trial in partnership with Tufts Medical Center. OK-101 is also being developed for use in dry eye disease.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss if Artificial Intelligence is ready for the clinic and the emergency room

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.

Matthew R. Starr, MD, discusses how secondary lens techniques have changed over time.

At the 2023 ASRS meeting in Seattle, Washington, Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study.

Richard B Rosen, MD, who is presenting New 'MacGyver-Inspired' Endolaser Option for Chandelier-Assisted Scleral Buckles at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

The month will be dedicated to educating families on the importance of healthy vision and early access to healthcare.

Samsung Bioepsis' SB15 was comparable to Eylea (aflibercept) in a 56-week randomized clinical trial that included a rerandomization at 32 weeks. The rerandomization resulted in 111 study volunteers switching from Eylea to the biosimilar for the last part of the study.

The research saw that new-onset full-thickness macular holes (FTMHs), especially those resulting from blunt ocular trauma, might close spontaneously without the need for a surgical intervention.

In presentations at the American Society of Retina Specialists 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

Cindy Cai, MD, who is presenting Health disparities in lapses in diabetic retinopathy care at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this presentation.

During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.